![Fig. 1. An 18-month longitudinal study of the index case demonstrating the effect of IFN therapy on viral titers and the prevalence of IgMκ B cells. / Prelevalence of IgMκ (percentage of lymphocytes) with HCV viremia genomic equivalents (gEs) per milliliter during treatment with IFN (3 MU given daily [qd] or 3 times weekly [tiw] as previously described5) are demonstrated. Relapse was associated with marked lymphocytosis (lymphocyte count of 44 × 109/L [44 000/μL]), which was due predominantly to IgMκ B cells; a high level of viremia (7.3 × 107gE/mL), and a cryocrit of 4%. WBCs declined from 53.4 × 109/L to 5.0 × 109/L and lymphocytosis from 82% (lymphocyte count of 44 × 109/L) to 38% (lymphocyte count of 1.9 × 109/L) with IFN therapy. Decreases in IFN therapy from daily to 3 times weekly administration and interruption of therapy were accompanied by parallel increases in viremia and monoclonal B cells. Cryoglobulinemia fell to 1% cryocrit after 1 month of therapy and remained at trace levels (less than 1%) for the next 17 months. LDH returned to normal in May 1998 and remained within normal range throughout the remainder of the patient's course of treatment.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/99/6/10.1182_blood.v99.6.2259/6/h80622276001.jpeg?Expires=1726834360&Signature=DdtxT9ZT0fA8UKK~~Tfj4PhdqftEgRxo2jG7J~m2PasO8MKOBWFPtdMuFe4csiqYRLpS3R38oTyQ054~3TIxpq2L1iTMGErMhlas0fS8qql-xKq1XBgTb2VtyeVM0RK2WQVlazpP7bV799Nhx2HlPl-u5a0wv0ua47ks3KnayKUYLJDvm85-XN4U9~feFa7xx-CkebbcxGW1I60G8NvxIp18wKbyP8Hp-hEhquacXqSXuhmY8wX8jVhKIkmbavl3sIM6P~gOn~7l9O6cpDCGZNvIBc~jIN4B8nLvPnwHl2ov3nb1urWT5A05Qym5Km1Ewqkv7eUmvZOuEop-jBFdKA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
An 18-month longitudinal study of the index case demonstrating the effect of IFN therapy on viral titers and the prevalence of IgMκ B cells.
Prelevalence of IgMκ (percentage of lymphocytes) with HCV viremia genomic equivalents (gEs) per milliliter during treatment with IFN (3 MU given daily [qd] or 3 times weekly [tiw] as previously described5) are demonstrated. Relapse was associated with marked lymphocytosis (lymphocyte count of 44 × 109/L [44 000/μL]), which was due predominantly to IgMκ B cells; a high level of viremia (7.3 × 107gE/mL), and a cryocrit of 4%. WBCs declined from 53.4 × 109/L to 5.0 × 109/L and lymphocytosis from 82% (lymphocyte count of 44 × 109/L) to 38% (lymphocyte count of 1.9 × 109/L) with IFN therapy. Decreases in IFN therapy from daily to 3 times weekly administration and interruption of therapy were accompanied by parallel increases in viremia and monoclonal B cells. Cryoglobulinemia fell to 1% cryocrit after 1 month of therapy and remained at trace levels (less than 1%) for the next 17 months. LDH returned to normal in May 1998 and remained within normal range throughout the remainder of the patient's course of treatment.
